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Background: The monoamines serotonin and dopamine are known to exist in two separate 
states: the endogenous state and the competitive inhibition state. The presence of the competitive 
inhibition state has been known to science for many years, but from a functional standpoint it 
has been noted in the literature as being “meaningless.”
Methods: A large database of monoamine transporter response to amino acid precursor 
administration variations with clinical outcomes was accumulated. In the process, a new organic 
cation transporter (OCT) model has been published, and OCT functional status determination 
along with amino acid precursor manipulation methods have been invented and refined.
Results: Methodology was developed whereby manipulation of the OCT, in the competitive 
inhibition state, is carried out in a predictable manner. This, in turn, has disproved the long-held 
assertion that the monoamine competitive inhibition state is functionally meaningless.
Conclusion: The most significant aspect of this paper is the documentation of newly recog-
nized relationships between serotonin and dopamine. When transport of serotonin and dopamine 
are both in the competitive inhibition state, manipulation of the concentrations of one will lead 
to predictable changes in concentrations of the other. From a functional standpoint, processes 
regulated and controlled by changes to only serotonin can now be controlled by changes to 
dopamine, and vice versa, in a predictable manner.
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Introduction
Serotonin and the catecholamines (dopamine, norepinephrine, and epinephrine) belong 
to a group of chemicals herein known as “monoamines.” The monoamines function 
independently, controlling and/or regulating bodily functions. These functions include, 
but are not limited to, neurotransmitter, neurohormone, regulatory, autocrine, paracrine, 
and autonomic control.1–3
This paper documents novel observations of the competitive inhibition state, which 
was previously thought to be functionally meaningless. The physiologic observations 
of this state are deemed the “apical regulatory super system” (APRESS), which occurs 
with simultaneous administration of serotonin and dopamine amino acid precursors 
in significant amounts.
“Super system” is defined as the fusion of two independent systems into one. 
Changes to one or more components of either system affect changes to all components 
in a predictable manner. In the balanced competitive inhibition state,3–8 serotonin and 
catecholamines undergo super system fusion.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Monoamines exist in one of three states: endogenous, 
unbalanced competitive inhibition, and balanced competitive 
inhibition.3–8 The “endogenous state” is achieved by dietary 
intake alone when no supplemental monoamine amino acid 
precursors are being administered.3–8
The competitive inhibition state cannot be achieved 
through dietary modification; it is established when signifi-
cant amounts of monoamine precursors are simultaneously 
administered.3–8 Competitive inhibition state literature 
notes “… functional relevance of the competitive inhibi-
tory effect … is most probably meaningless.”9 Functional 
relevance is achieved with the ability to assay and regu-
late transport of the monoamines in a predictable manner 
with organic cation transporter (OCT) functional status 
  determination. Except by random chance, it is impossible 
to achieve the balanced competitive inhibition state without 
OCT functional determination.3–8 Differentiating “unbal-
anced” and “balanced” competitive inhibition is discussed 
later in this paper.
The foundation of APRESS is that in the competitive 
inhibition state, transport changes to one monoamine lead to 
predictable changes in all monoamines. These changes are not 
intuitive. Endogenous state observations are not applicable to 
APRESS (see Tables 1–4). This writing introduces APRESS 
as a novel physiologic state adhering to unique transporter 
properties that are counterintuitive to rules of the endogenous 
state. This paper discusses only the following limited aspects 
of monoamine interaction in APRESS.
•	 Functions impacted and/or controlled in the endogenous 
state only by changes in serotonin concentrations may 
also be impacted or controlled by changes in dopamine 
concentrations in APRESS.
•	 Functions impacted and/or controlled in the endogenous 
state only by changes in dopamine concentrations may 
also be impacted or controlled by changes in serotonin 
concentrations in APRESS.
Methods and materials
Since 2009, the authors of this paper have published eleven   
peer-reviewed original research papers relating to the simul-
taneous manipulation of the serotonin and catecholamine 
systems with amino acid precursors under guidance of OCT 
assay interpretation.3–8,10–14 APRESS embodies the common 
thread of these writings: serotonin and catecholamine fusion 
into one system. Previous publications outlined much of 
the novel scientific foundation of APRESS, but its impact, 
novel abilities and other considerations have not been fully 
explored and documented.
Following are research components used to define the 
novel physiologic attributes of APRESS in the body. These 
components, observations, and networking applications 
include, but are not limited to:
•	 Over 1000 monoamine databases relating to the 
  endogenous and competitive inhibition states.15
•	 A master database documenting over 2 million patient-days 
of monoamine amino acid transporter manipulation.15
•	 Review and interpretation of over 100,000 urinary 
  monoamine assays in the endogenous or competitive 
inhibition state.15
•	 Defining the three-phase monoamine transporter response 
of serotonin and dopamine observed during simultaneous 
administration of their precursors.3–8,10–14
•	 A network of over 1000 physicians manipulating nutrients 
in APRESS.15
Serotonin and dopamine filtered at the glomerulous are 
metabolized by the kidneys; significant amounts do not make 
it into the final urine. Newly synthesized renal serotonin and 
dopamine meet one of two fates, as illustrated in Figure 1. 
The three-phase response of urinary monoamines is used to 
determine the functional status of the basolateral OCT2 of the 
proximal convoluted renal tubule cells.3–8,10–14 Urinary levels 
are dependent upon the interaction of the basolateral OCT2 
and the apical OCTN2 in transporting newly synthesized 
monoamines out of the proximal convoluted renal tubule 
cells (see Figure 1).3–8,11,12,16
Proper OCT interpretation requires obtaining two or 
more urinary monoamine assays while taking significant 
amounts of varied precursor dosing values consistently for 
5 days minimum to achieve equilibrium. Serial assays are 
then compared to determine the impact of precursor dosing 
value changes.3–8,10–14
The following urinary monoamine values were reported 
in µg of monoamine per g of creatinine to compensate for 
specific gravity fluctuations. A urinary serotonin or dopamine 
Table 1 impact of increasing amino acid precursor dosing values of system A in phase 3
Amino acid intake Synthesis Metabolism Transport Post transporter Urinary
system A increased increased increased increased increased increased
system B same Decreased increased Decreased Decreased increased
Note: The response to increasing one monoamine precursor of serotonin or dopamine in competitive inhibition.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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value less than 80 or 475, respectively, is defined as a phase 2 
response. A urinary serotonin or dopamine value greater than 
80 or 475, respectively, is interpreted as being in phase 1 or 
phase 3. If a direct relationship is found between amino acid 
dosing and urinary assay response, it is a phase 3 response. 
An inverse correlation is a phase 1 response. The phase 3 
therapeutic range for urinary serotonin is 80–240. The phase 3 
therapeutic range for urinary dopamine is 475–1100.3–8,10–14
Urine samples were collected 6 hours prior to bedtime 
after a minimum of 1 week on a specific dosing value, with 
no missed doses of amino acid precursors. The most frequent 
collection time point was 4 PM. Samples were stabilized 
in 6 N HCl to preserve the monoamines and shipped to 
DBS Laboratories (Duluth, MN) which is operated under 
the direction of one of the authors (Thomas Uncini, MD). 
Urinary monoamines were assayed utilizing commercially 
available radioimmunoassay kits (3 CAT RIA IB88501 and 
IB89527, both from Immuno Biological Laboratories, Inc, 
Minneapolis, MN). The DBS laboratory is accredited as a 
high complexity laboratory by Clinical Laboratory Improve-
ment Amendments. OCT assay interpretation was performed 
by one of the authors (Marty Hinz).3–8,10–14
Results
Three primary functions affect intracellular and extracellular 
serotonin and catecholamine levels: synthesis, metabolism, 
and transport.3–5,7,8,10–12 These functions occur in either the 
endogenous or competitive inhibition state.3–8
The relationship between serotonin and dopamine regard-
ing synthesis, metabolism, and transport in the endogenous 
state appears to be random. Matched pairs t-test analysis 
of endogenous urinary monoamines reveals significant 
  day-to-day changes (P , 0.05) in a subject. In the competitive 
inhibition state, predictable changes occur to all monoamine 
components with changes to individual precursor dosing 
values of either system.6,10,12
Aromatic L-amino acid decarboxylase (AAAD) catalyzes 
serotonin and dopamine synthesis. Monoamine oxidase 
(MAO) catalyzes metabolism of serotonin and dopamine. 
OCT transports monoamines and their precursors in and out 
of proximal convoluted renal tubule cells. When significant 
amounts of balanced serotonin and dopamine precursors are 
administered simultaneously under guidance of OCT assay 
optimization, the balanced competitive inhibition of APRESS 
is established.6,10,12
Immediate precursors of serotonin and dopamine present-
ing at the AAAD need to be in balance. If not, precursors of 
one system will dominate AAAD, compromising nondomi-
nant monoamine synthesis.6,10,11
Serotonin and dopamine need to be in balance or the 
dominant monoamine increases MAO activity and metabo-
lism of the nondominant system.6,10,12
Monoamine renal physiology is complex. Prior to the 
authors writing this paper, the sequence of events from the 
monoamines and their precursors being filtered at the glom-
erulous to them appearing in the system or final urine had 
not been documented.
Until this research, direct clinical measurement and 
evaluation of monoamine OCT functional status did not 
exist, rendering the competitive inhibition state functionally 
meaningless.9
Serotonin, dopamine, and their precursors filtered at the 
glomerulous are taken up from the proximal tubules by OCT2 
transporters into the proximal convoluted renal tubule cells 
where the monoamines are metabolized. Significant amounts 
do not make it to the final urine under normal conditions.3–8,11,12 
Precursors are then synthesized into new monoamines, which 
are preferentially transported by the basolateral OCT2 to the 
system or excreted via the apical OCTN2 as urinary waste. 
Interpretation of urinary monoamine levels in the competitive 
inhibition state is an interpretation of the functional status of 
the basolateral OCT2.3–8,11,12
Previous writings by the authors of this paper refined 
the basolateral OCT2 transporter model.3 The OCT of 
the liver, kidneys, bowels, and brain are “identical and 
Table 2 impact of decreasing amino acid precursor dosing values of system A in phase 3
Amino acid intake Synthesis Metabolism Transport Post transporter Urinary
system A Decreased Decreased Decreased Decreased Decreased Decreased
system B same increased Decreased increased increased Decreased
Note: The response to decreasing one monoamine precursor of serotonin or dopamine in competitive inhibition.
Table 3 Urinary monoamine concentrations per phase
Serotonin Dopamine
Phase 1 .80 .475
Phase 2 ,80 ,475
Phase 3 .80 .475
Phase 3 therapeutic ranges
serotonin Dopamine
80–240 475–1100
Note: Units are in µg of monoamine per g creatinine.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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homologous.” Precursors cross the blood–brain barrier 
then come to equilibrium throughout the body.16 Under 
the dual gate lumen transporter model, there are separate 
serotonin and dopamine gates at the lumen entrance. 
These gates independently regulate lumen access by the 
respective monoamine. While either gate can be partially 
closed, blocking access, both gates are never simultane-
ously partially closed.3
Serotonin and dopamine basolateral OCT2 transport 
exists in three transport phases. In phase 1 the entrance gate 
is partially closed, restricting access to the nonsaturated 
lumen. If the gate at the lumen is partially closed (phase 1), 
it will open as the total amount of serotonin and dopamine 
presenting at the transporter increases. In phase 2 the gate 
of the nonsaturated lumen is open. In phase 3 the entrance 
gate of the saturated lumen is open.3–8,10–14
Now the question becomes: how can functions controlled 
only by serotonin or dopamine in the endogenous state be 
controlled in a predictable manner by changes to either in 
the competitive inhibition state?
Once the transporter is saturated with both serotonin and 
dopamine (phase 3), an increase in one monoamine being 
transported will cause the amount of the other monoamine 
being transported to decrease. Tables 1 and 2 document the 
Basolateral
transporters
(OCT2)
Apical
transporters
(OCTN2)
To final urine
To
renal
vein
Serotonin newly
synthesized by
the kindey
Dopamine newly
synthesized by
the kidney
The newly synthesized
serotonin and dopamine are
preferentially transported out of
the proximal convoluted renal
tubule cells by the basolateral
transporters (OCT2)
The serotonin and dopamine
not transported by the
basolateral transporter are
transported as waste to the
final urine via the apical
transporters (OCTN2)
Figure 1 The interaction of OcT2 and OcTN2. Newly synthesized serotonin and dopamine are transported preferentially by the basolateral OcT2. Functional status of the 
OCT2 is determined by assaying the urinary monoamines not transported by the OCT2, which are transported by the OCTN2 to the final urine as waste.3–8,11
Abbreviation: OcT, organic cation transporter.
Table 4 effect of increasing only L-dopa dosing values in the competitive inhibition state
Day # Urinary  
serotonin
Urinary  
dopamine
Serotonin  
phase
Dopamine  
phase
5-HTP mg/day  
dosing value
L-dopa mg/day   
dosing value
0 (test 1) 84 289 3 2 900 120
8 (test 2) 473 786 3 3 900 360
Notes: serotonin phase 3/3; Dopamine phase 2/3; units are in µg of monoamine per g creatinine.
Abbreviation: HTP, hydroxytryptophan.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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impact of placing both systems into competitive inhibition 
as verified by OCT assay determination.3–8,10–14
In Tables 1 and 2, “System A” is either L-dopa or 
5-hydroxytryptophan (immediate dopamine and serotonin 
precursors respectively), with “System B” the opposite 
precursor. With both systems in phase 3, a single   precursor 
increase leads to a decrease in the post-transporter levels of 
the other system through competitive inhibition, just as a 
decrease of one amino acid precursor leads to an increase in 
post-transporter levels of the other system. In the competitive 
inhibition state, these levels can be changed by making 
changes to amino acid precursor dosing values of either 
system.
Interpretation of urinary levels of serotonin and dopamine, 
with amino acid dosing changes in the competitive inhibi-
tion state, are complex. In Table 1, the precursor increase 
causes decreased synthesis of the nondominant monoamine 
(system B) through AAAD competitive inhibition. Increased 
activity of the MAO enzyme system is induced, leading to 
increased metabolism of the nondominant monoamine.
The key to optimal balanced control is to place the 
serotonin and dopamine in the therapeutic phase 3 ranges 
of Table 3. This cannot be done empirically. The dosing 
levels of 5-hydroxytryptophan (5-HTP) need to reach the 
phase 2/phase 3 inflection point between 37.5 and 2400 mg 
per day.15 The L-dopa dosing level to reach this inflection 
point is between 30 and 2100 mg per day. Dosing values 
of serotonin precursors are independent from dopamine 
precursors, meaning any combination of precursors in a 
large spectrum is possible. OCT assay to determine levels 
of serotonin and dopamine not transported by the basolateral 
OCT2 is required.3–8,10–14
In test 1 of Table 4, serotonin is phase 3 and dopamine 
transport is phase 2. Between tests, L-dopa was increased to 
360 mg per day, causing an increase in dopamine transported 
by the OCT2 and in the urine. Less serotonin was then 
transported by the OCT2 as dopamine transport increased, 
excluding serotonin from the OCT2 transporter through 
competitive inhibition, and more serotonin appeared in the 
final urine as waste. In the first assay, serotonin was 84 µg of 
serotonin per g creatinine and in phase 3. An increase in L-dopa 
leads to a decrease in the serotonin phase 2/phase 3 inflection 
point (inverse relationship). The same is true regarding 5-HTP 
increases and the dopamine phase 2/phase 3 inflection point.
In test 2, APRESS effect is not optimal. The urinary 
serotonin is too high, causing excessive exclusion of 
dopamine transport even though the dopamine is in the 
therapeutic range. Optimal serotonin and dopamine 
transport is seen only with both serotonin and dopamine in 
their phase 3 therapeutic ranges. Even though on test 2 the 
urinary dopamine is in the phase 3 therapeutic range, this 
observation is meaningless until both serotonin and dopamine 
are simultaneously in therapeutic ranges. If both systems are 
not in therapeutic phase 3 ranges defined in Table 3, further 
optimization is needed to maximize transporter balance. 
With the lowering of daily 5-HTP dosing values due to 
OCT2 transporter imbalance, the urinary dopamine levels 
at the OCTN2 transporter entrance will drop secondary 
to decreased serotonin transport, facilitating increased 
dopamine transport. This causes less serotonin and dopamine 
to show up in the final urine as waste. The general direction of 
urinary serotonin levels in transport and final urinary levels 
can be predicted in the competitive inhibition state; the exact 
amount of movement secondary to amino acid precursor 
changes, however, is individualized.3–8,10–14
Full interpretation of large-scale results may be quite 
confusing at times for the uninitiated. Extraordinarily 
complex relationships not covered in this writing exist 
based on determination of OCT2 transporter status. These 
complexities are beyond the scope of this paper.3–8,10–14
The unbalanced competitive inhibition 
state, a pathologic state
The hallmark of the unbalanced competitive inhibition state 
is “pathological depletion of monoamine components.” 
When unbalanced amino acid precursors are administered, 
one system dominates and the other is nondominant. The 
dominant system overwhelms and depletes the nondominant 
system. Most significant depletions occur in weeks or months 
although some may take years.4,5,8,10,11
•	 L-tryptophan or 5-HTP depletes dopamine when domi-
nant.4,5,8,10,11
•	 L-tyrosine or L-dopa depletes serotonin when domi-
nant.4,5,8,10,11
L-dopa and 5-HTP are the immediate dopamine and sero-
tonin precursors, respectively. Both are synthesized into the 
monoamine without biochemical feedback regulation.7 The 
following clinical situation illustrates unbalanced depletion 
of a nondominant system.
In Parkinson’s disease, serotonin and dopamine are 
depleted by the disease. L-dopa treatment alone leads to 
serotonin depletion by inhibiting serotonin AAAD synthesis. 
Administering only L-dopa increases the activity of the MAO 
system, depleting the nondominant serotonin when balanced 
levels of 5-HTP are not being administered. Side effects 
associated with administration of only L-dopa, which are Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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related to serotonin imbalance, include but are not limited 
to tachyphylaxis due to serotonin depletion, problems of 
improperly balanced monoamines, problems caused by 
dopamine fluctuations, and problems resulting from sulfur 
amino acid depletion.7
Problems associated with dominant levels of 5-HTP are a 
mirror image of the L-dopa problems. The common   practice 
of administering only 5-HTP without properly balanced 
dopamine precursors depletes dopamine.7
Discussion
Functions dependent on only serotonin or dopamine 
concentrations in the endogenous state can be impacted in 
a predictable manner by changes in levels of either in the 
balanced competitive inhibition state which is the foundation 
of APRESS.4,5,8,10,11 APRESS physiology is not intuitive. 
An intimate knowledge of monoamine physiology in the 
endogenous state may even be a distraction to mastering 
the complex state of APRESS. Observations and rules 
formulated for the endogenous and unbalanced competitive 
inhibition states are typically not valid in guiding amino acid 
precursor adjustments.3–8,10–14
The physiological and clinical management observations 
entered into the APRESS catalog have just started. It contains 
the following:
•	 Functions controlled by dopamine in the endogenous 
state can be controlled with changes to serotonin and vice 
versa.
•	 The balanced approach does not deplete monoamines.3–8,10–14
•	 Administration of targeted and balanced amino acid 
  precursors leads to optimal results in disease and dysfunction 
management.3–8,10–14
•	 The approach directly addresses and treats the cause of 
problems, unlike the symptom management approach 
with prescription drugs.3–8,10–14
•	 Properly balanced serotonin and dopamine does away 
with side effect dosing value barriers providing the 
opportunity to reach levels of needed amino acid intake 
not possible in the unbalanced state.3–8,10–14
•	 Parkinson’s disease patients can be treated with L-dopa 
levels needed to control symptoms without reaching a 
side-effect induced dosing barrier.7
•	 Management of the extensive list of side effects 
associated with L-dopa and carbidopa in treatment of 
Parkinson disease.7
•	 Bipolar disorder cycling on the depressive pole can be 
differentiated from major affective disorder then treated 
effectively.11
•	 Refractory depression can be successfully treated without 
drug side effects.
•	 In Crohn’s disease, OCT genetic transporter defects that 
cause Crohn’s symptoms and interstitial colonic serotonin 
to be markedly elevated can be treated.4
•	 Attention deficit hyperactivity disorder preliminary 
treatment studies (N = 85) published in 2011 reveal efficacy 
results greater than atomoxetine or methylphenidate.5
Conclusion
Serotonin and dopamine may exist in three basic states: the 
endogenous state, the unbalanced competitive inhibition state, 
and the balanced competitive inhibition state.   Physiologic 
observations in the endogenous state have no bearing or 
relationship with the competitive inhibition state.
The balanced competitive inhibition state is the foundation 
for APRESS. APRESS is a registry of the activities impacted 
by manipulating the balanced competitive inhibition state. 
The ability to affect and regulate bilateral serotonin or 
dopamine concentration changes with a single monoamine 
adjustment in a predictable manner is the foundation of 
APRESS. This leads to the ability to define interactions and 
gain control in a physiologic state that until now was thought 
to be functionally meaningless.
APRESS is indeed based on a unique physiologic state 
that is not meaningless. It is a new frontier that cannot be 
achieved through dietary manipulation alone or without 
OCT functional status determination, a procedure that can 
be performed in medical clinics.
APRESS is not a state that can be optimally achieved by 
empirical administration of amino acid precursors. Once in this 
clinical competitive inhibition state, the scientific observations 
of the endogenous state are no longer valid. APRESS is a new 
physiological world in and of itself. It is in need of research to 
define its far-reaching parameters and implications. It is the 
goal of this writing to stimulate interest and discussion relating 
to this novel state known as APRESS.
Disclosure
MH owns NeuroResearch Clinics, Inc; AS reports no 
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